Some biologics, such as ustekinumab (Stelara) and infliximab (Remicade), were found to be safe and effective for patients with erythrodermic psoriasis in a recent study published in the Journal of the American Academy of Dermatology.
In the systemic review, the researchers analyzed treatment response and tolerability of biologic medications in 43 studies with a total of 179 patients with erythrodermic psoriasis. Baseline Psoriasis Area Severity Index (PASI) score, PASI improvement score, and adverse events were reported, and adequate treatment was defined as PASI ≥ 50.
Most patients responded at some point during treatment, the researchers said. They found a higher level of evidence supported the effectiveness of infliximab, ustekinumab, ixekizumab (Taltz), and guselkumab (Tremfya).
The most commonly reported adverse event was infection (n=35), the researchers said.
“Patients with erythrodermic psoriasis treated with biologics demonstrated positive responses and treatment was well-tolerated with a weak recommendation and limited quality of evidence in favor of infliximab, ustekinumab, ixekizumab, and guselkumab,” they concluded.
Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: A systematic review [published online April 2, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.073